gMendel® announces CE marking for its Phivea® v1.0.0 platform - #BHHMembersInitiatives
Home News gMendel® announces CE marking for its Phivea® v1.0.0 platform - #BHHMembersInitiatives

gMendel® announces CE marking for its Phivea® v1.0.0 platform - #BHHMembersInitiatives

MAY 6, 2022 BHH News
BHH member gMendel®, a Danish medical technology startup aiming to transform the diagnosis of genetic disorders for better disease management, announced today it has achieved CE marking for its Phivea® v1.0.0 platform, a novel screening technology for the detection of Klinefelter Syndrome. Following the successful validation and a comprehensive performance evaluation, documenting the clinical applicability of its technology, gMendel® is now entitled to sell the Phivea® v1.0.0 platform in the EU, starting with a registration in Denmark. The Phivea® v1.0.0 platform will be marketed as an In Vitro Diagnostic (IVD) medical device product under the Directive 98/79/EC for In Vitro Diagnostic medical devices. “The CE marking of the Phivea® v1.0.0 platform is a major milestone for gMendel®”, said Zoran Velkoski, co-founder of gMendel®. “In parallel with our strong patent portfolio strategy, our recently-obtained ISO 13485 certification and the CE marking pave the way for the commercial launch of more advanced products in the highly competitive IVD market, as defined in our product roadmap”, explained Zoran Velkoski.  About the Phivea® v1.0.0 platform Phivea® v1.0.0 is an in vitro screening software tool for the diagnosis of Klinefelter syndrome based on DNA sequencing process. It offers screening tests capabilities, based on the data coming from third-party genome sequencers. Phivea® employs advanced Artificial Intelligence and customized Deep Learning architectures at all levels of the learning process, from feature extraction to assessment and follow-up care. Following a multi model fusion strategy, the Platform combines outcomes of individual models into a single, accurate medical interpretation. More about Phivea® v1.0.0 here. About CE marking for medical devices Many products require CE marking before they can be sold in the EU. CE marking indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. The CE marking affixed to a medical device demonstrates compliance with the EU legislation in force and therefore can be made available for distribution or use, e.g. to a distributor, healthcare professional or patient. More about CE marking in medical devices here.  
June 12, 2024 BHH News
Siemens Healthineers and Barcelona Health Hub sign partnership to drive breakthrough innovations for equitable, quality healthcare
This partnership opens a collaboration line between both entities to advance towards a future where medical care and technological advancements help healthcare professionals deliver high-quality care, thus achieving the best possible outcomes for patients.
Read more
June 10, 2024 BHH News
Menarini and Barcelona Health Hub join forces to promote the incorporation of digital health innovation into the healthcare field
Open collaboration and co-creation are the pillars for generating innovation in healthcare. Technological and scientific advances can be significantly accelerated when collaborative environments are fostered.
Read more
June 06, 2024 BHH News
BHH Podcast - Mediktor
BHH member Mediktor joins in this episode with CEO Cristian Pascual.  Listen to Cristian share his journey in revolutionizing healthcare through AI-driven medical triage. 
Read more
June 05, 2024 BHH News
CHV-FHSC signs a strategic alliance with Barcelona Health Hub
This alliance is to carry out joint activities to share concerns and knowledge that lead to the development of new technology projects.
Read more
June 05, 2024 BHH News
BHH ON AIR with Vodafone Business at Revolució 4.0 at Catalunya Ràdio
If you’re looking for a quick catch-up about all things related to digital health, don’t miss BHH this weekend at Catalunya Ràdio!
Read more
May 29, 2024 BHH News
Teladoc Health joins Barcelona Health Hub to support its mission to advance innovation in digital health
Teladoc Health, the world's leading virtual care company, with revenues of 2.6 billion USD in 2023, joins Barcelona Health Hub. 
Read more
May 22, 2024 BHH News
Check out the state of Digital Health in Catalonia
This is your chance to dive deep into the state of digital health in Catalonia with this elaborated by ACCIÓ, in collaboration with Barcelona Health Hub.
Read more
May 09, 2024 BHH News
Explore the 'Sandbox of the System' at the Stage Hospital de la Santa Creu i Sant Pau
Explore the Hospital de la Santa Creu i Sant Pau Stage as the latest track of the Health Revolution Congress on May 16th!
Read more
May 09, 2024 BHH News
BHH ON AIR with Fundació Sant Pau at Revolució 4.0 at Catalunya Ràdio
If you’re looking for a quick catch-up about all things related to digital health, don’t miss BHH this weekend at Catalunya Ràdio!
Read more
May 03, 2024 BHH News
Stage Biocat: New Pathways for the Adoption of Healthcare Innovation in Catalonia
Discover the Biocat morning session as part of the Health Revolution Congress on May 16th.
Read more